Road map for fibrolamellar carcinoma: progress and goals of a diversified approach

Fibrolamellar carcinoma is a rare liver cancer, which primarily afflicts adolescents and young adults worldwide and is frequently lethal. Given the rarity of this disease, patient recruitment for clinical trials remains a challenge. In November 2017, the Second Fibrolamellar Cancer Foundation Scient...

Descripción completa

Detalles Bibliográficos
Autores principales: Kastenhuber, Edward R, Craig, John, Ramsey, Jon, Sullivan, Kevin M, Sage, Julien, de Oliveira, Sofia, Riehle, Kimberly J, Scott, John D, Gordan, John D, Bardeesy, Nabeel, Abou-Alfa, Ghassan K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Meeting Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362920/
https://www.ncbi.nlm.nih.gov/pubmed/30951568
http://dx.doi.org/10.2147/JHC.S194764
Descripción
Sumario:Fibrolamellar carcinoma is a rare liver cancer, which primarily afflicts adolescents and young adults worldwide and is frequently lethal. Given the rarity of this disease, patient recruitment for clinical trials remains a challenge. In November 2017, the Second Fibrolamellar Cancer Foundation Scientific Summit (Stamford, CT, USA) provided an opportunity for investigators to discuss recent advances in the characterization of the disease and its surrounding liver and immune context. The Fibrolamellar Cancer Foundation has thus set out a road map to identify and test therapeutic targets in the most efficient possible manner.

Ejemplares similares